NCT02367638View on ClinicalTrials.gov

Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

July 31, 2015

Conditions
Varicella (Chicken Pox)
Interventions
BIOLOGICAL

MG1111

Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection

BIOLOGICAL

VARIVAX

VARIVAX is administered by subcutaneous injection

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY

NCT02367638 - Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults | Biotech Hunter | Biotech Hunter